- JointSphere raises capital through Brabant Startup Fund and informal investors
- Norwegian Visma Group acquires Dutch cloud software provider EBPI
- Gilde Buy Out Partners acquires majority stake in Elcee Group
- EXASUN raises growth capital at ING, ENERGIIQ and ABN AMRO
- Vanquish Yachts sells majority stake to Dutch private equity firm Transequity Network
- SectorMedical Care
- ActivityMedical technology
- Date12 April 2019
JointSphere raises capital through Brabant Startup Fund and informal investors
JointSphere, founded in 2012 and headquartered in Eindhoven, is a Dutch medtech company dedicated to the development of innovative medical devices for cartilage repair. Its proprietary technology enables replacement and regeneration of damaged articular cartilage, promising a long-term functional repair of the cartilage lining of the joints.
The current lead project, aimed at cartilage defects in the knee, is a breakthrough compared to all current treatments because of its long-term treatment effect. This will not only decrease the amount of repeat treatments but will also reduce the number of knee replacements with artificial joints and subsequent revision surgeries. Besides the clear benefits for the individual patients JointSphere’s technology will have a huge positive impact on health care budgets as well. Recently it has successfully completed the Proof of Concept phase in an animal (equine) study in which it performed above expectation in a functional sense.
In order to be able to initiate the pre-clinical validation phase for its lead project JointSphere successfully raised additional funding. A loan from the combination of Brabant Startup Fund (BSF) and an investment from Stapel JS Ventures, a consortium of informal investors, provided JointSphere with sufficient funds to establish the final product design and bring the project up to the clinical development phase in the next two years. For the clinical development phase an additional financing round will be closed.
Ward van Buul, CEO of JointSphere: “We’re happy that this investment round enables us to complete the pre-clinical validation phase in the coming two years. We think that Brabant Startup Fund and Stapel JS Ventures will bring added value given their experience, expertise and broad network. We’re looking forward to this last step before entering the clinical development phase. Ultimately our goal is to obtain a CE marking within 4 to 5 years."
For more information: JointSphere